This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IntegraMed America Presentation At Oppenheimer Healthcare Conference - Transcript

IntegraMed America ( INMD)

Presentation at Oppenheimer Healthcare Conference

December 14, 2011 2:10 p.m. ET


Jay Higham - CEO


Matt [Nuremberg] - Oppenheimer


Matt [Nuremberg]

Welcome to the 22nd Annual Healthcare Conference. I’m Matt [Nuremberg] with the Healthcare Services Team, and I’d like to introduce IntegraMed. We have with us from the company, CEO Jay Higham.

Jay Higham

Thank you very much. Thanks to Oppenheimer for inviting us to this conference. We appreciate being here. I’m going to take a few minutes to walk through this slide deck and try to leave some time at the end for people to ask questions.

IntegraMed is a healthcare services company. We were founded in 1985, so we’re very well established in the United States. We operate in two highly fragmented segments of healthcare, the fertility services field and the varicose vein treatment.

On a combined basis, these two verticals represent about a $6 billion market in the United States, and IntegraMed is the largest provider in both those two segments. We have very little national competition. Both of them are very competitive in each local market, but from a national level there’s nobody that’s doing quite what we do.

We do have that national footprint, and we have rapid growth really driven three ways, through patient acquisition; through de novo new clinic openings, where we’re launching new clinics in major markets across the country; and also in strategic acquisitions. And we have a strong track record in all three components of the growth. That’s resulted over the last five years in compound average top line growth approaching 14% and EBITDA just over 14%.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs